Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Pocket Test Measures Fifty Diagnostic Parameters

By LabMedica International staff writers
Posted on 03 Jan 2013
A small device could allow health care providers to test for insulin and other blood proteins, cholesterol, and even signs of viral or bacterial infection simultaneously. More...


The novel device is about the size of a business card and is called the multiplexed volumetric bar-chart chip or V-chip and uses as little as one µL of blood for all the point-of-care- tests.

Scientists at the Methodist Hospital Research Institute (Houston, TX, USA) developed the V-chip, which is composed of two thin pieces of glass that are about 7.6 cm by 5.1 cm. In between are four wells: for hydrogen peroxide; for up to 50 different antibodies to specific proteins, DNA or RNA fragments, or lipids of interest, and the enzyme catalase; for serum or other sample; and for a suitable dye. Initially, the wells are kept separate from each other. A shift in the glass plates brings the wells into contact, creating a contiguous, zigzagged space from one end of the V-chip to the other.

When the substance of interest, such as insulin, binds to antibodies bound to the glass slide, catalase is made active and splits nearby hydrogen peroxide into water and oxygen gas. This approach resembles enzyme-linked immunosorbent assay (ELISA) methods. The oxygen pushes the dye up the column. The more insulin present, the more oxygen is created, and the farther dye is pushed up the slide. Tests show that distance is more or less proportional to the amount of substrate present. The end result is a visual bar chart. The device is easy to read and accurate.

Lidong Qin, PhD, the project's principal investigator, said, "The V-Chip could make it possible to bring tests to the bedside, remote areas, and other types of point-of-care needs. V-Chip is accurate, cheap, and portable. It requires only a drop of a sample, not a vial of blood, and can do 50 different tests in one go. The sensitivity of the V-chip can be improved if narrower and longer bar channels are used. Our next steps are to make the device more user friendly and be so simple to use, it barely needs instructions." The study was published on December 18, 2012, in the journal Nature Communications.

The Methodist Hospital Research Institute


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.